Skip to main content

Berkeley HeartLab Inks Heart Dx Pact with Geisinger

NEW YORK (GenomeWeb News) – Celera subsidiary Berkeley HeartLab said yesterday that Geisinger Medical Center and a clinical lab service recently started by Geisinger Health System will use some of its cardiovascular diagnostic tests and services.

Under a co-marketing agreement, Geisinger Health System's Proven Diagnostics lab service will provide BHL's 4myheart cardiovascular disease management program and select tools from BHL's menu of cardiovascular tests and services. Proven Diagnostics and Geisinger Medical Center also will have access to BHL's KIF6 test.

The KIF6 is a genetic test for a gene that encodes kinesin-like protein 6 that has been associated with cardiovascular risk and statin benefit, the company said.

"By combining Proven Diagnostics' leading capabilities with our innovative content and services, such as KIF6 and 4myheart, we believe we provide a more personal approach to cardiovascular disease management," Chris Hall, senior vice president of Berkeley HeartLab, said in a statement.

Financial terms of the agreement were not released.

Celera announced the pact on the same day that it released a third-quarter report showing that revenue for the BHL business had fallen 26 percent year-over-year to $24.2 million from $30.1 million.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.